Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLL

What Is the Best Strategy for Frontline Venetoclax Plus Obinutuzumab in CLL?Подробнее

Current and emerging treatment strategies for CLL & defining the optimal treatment durationПодробнее

Comparing continuous and fixed duration therapy in CLLПодробнее

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses CIT in frontline CLLПодробнее

The optimum approach to frontline treatment of CLL in 2021Подробнее

Clinical trials of fixed duration treatments & novel targets in CLLПодробнее

The future of fixed-duration therapy in CLLПодробнее

CLL14: feasibility of fixed-duration frontline therapy in CLLПодробнее

Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLLПодробнее

Venetoclax-obinutuzumab is superior to chemoimmunotherapy in frontline CLL: updates from GAIA/CLL13Подробнее

GLOW: primary analysis of ibrutinib plus venetoclax versus obinutuzumab plus chlorambucil in CLLПодробнее

The Role of Venetoclax + Rituximab in CLLПодробнее

The role of venetoclax in the treatment of CLLПодробнее

Obinutuzumab + Venetoclax for Frontline CLLПодробнее

CLL14: Venetoclax plus obinutuzumab in untreated CLLПодробнее

Comment on fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbiditiesПодробнее

GLOW trial: Is fixed duration ibrutinib + venetoclax a feasible frontline treatment option for CLL?Подробнее

Frontline ibrutinib + venetoclax in CLL: Results from a fixed duration cohort of the CAPTIVATE studyПодробнее

Venetoclax and Obinutuzumab in CLLПодробнее

Venetoclax-Obinutuzumab vs Chlorambucil-Obinutuzumab To Treat CLLПодробнее